Pharmaceutical Manufacturing 2026Updated

List of GMP-Certified Peptide Synthesis Contract Manufacturers

Comprehensive directory of cGMP-certified CDMOs offering peptide API synthesis for clinical and commercial supply. Ideal for pharma/biotech CMC teams sourcing outsourced peptide manufacturing partners.

Available Data Fields

Company Name

Headquarters

GMP Certifications

Synthesis Scale (SPPS Capacity)

Annual Production Capacity

Regulatory Inspections Passed

Clinical Phase Support

Peptide Modifications Offered

Global Facility Locations

Key Therapeutic Areas

Data Preview

* Full data requires registration

Company Name	Headquarters	GMP Certifications	Annual Production Capacity
Bachem AG	Bubendorf, Switzerland	FDA, EMA, PMDA	>1 metric ton/year
PolyPeptide Group	Baar, Switzerland	FDA, EMA, KFDA	Multi-kg to metric ton scale
CordenPharma International	Basel, Switzerland	FDA, EMA (HLfGP)	42,000 L SPPS capacity (by 2028)
AmbioPharm	North Augusta, SC, USA	FDA (5 inspections passed)	Up to 1 metric ton/year
CPC Scientific	Sunnyvale, CA, USA	FDA, NMPA, EMA, TGA	>1,000 kg/year

85+ records available for download.

* Continue from free preview

GMP-Certified Peptide Synthesis: The CDMO Landscape

The global peptide therapeutics CDMO market surpassed USD 3.8 billion in 2024 and is projected to reach USD 16.7 billion by 2032, driven by the surge in GLP-1 agonists, peptide-drug conjugates, and over 170 peptide candidates currently in clinical trials. For CMC directors at pharma and biotech companies, identifying the right GMP-certified contract manufacturer is a critical path decision that directly impacts IND timelines and commercial supply security.

Capacity Expansion Race

The industry is experiencing an unprecedented capacity build-out. CordenPharma announced a EUR 900 million investment to more than double its SPPS reactor capacity to 42,000 L by 2028. Bachem is constructing a new large-scale facility in Bubendorf, Switzerland, alongside expansions at its Vista, CA site. PolyPeptide Group invested approximately EUR 100 million in modular expansion at its Malmö, Sweden facility, doubling SPPS capacity. These expansions reflect the structural supply deficit created by the commercial success of semaglutide and tirzepatide.

Key Selection Criteria for CMC Teams

Criterion	Why It Matters
Regulatory track record	FDA/EMA inspection history directly correlates with filing risk
Scale flexibility	Toxicology batch (grams) to commercial supply (metric tons) under one roof
Technology platform	Solid-phase (SPPS), solution-phase, hybrid, or continuous flow capabilities
Analytical & CMC support	In-house method development, stability studies, and regulatory filing support
Supply chain resilience	Multi-site manufacturing, raw material sourcing, and geographic diversification

Regional Landscape

North America and Europe account for over 85% of global GMP peptide manufacturing capacity. Switzerland alone hosts the headquarters of three of the top five CDMOs (Bachem, PolyPeptide, CordenPharma). The Asia-Pacific region is gaining ground, with players like Sinopep Biopharma and GenScript scaling GMP capabilities to serve global sponsors.

Frequently Asked Questions

Q.How does the data collection work for this manufacturer list?

When you submit a request, our AI crawls the public web in real time—company websites, regulatory databases, industry directories, and press releases—to compile and structure the latest information on GMP-certified peptide CDMOs.

Q.Does the dataset include pricing or cost-per-gram information?

Pricing for contract peptide manufacturing is typically confidential and project-specific. Our dataset focuses on publicly available information such as certifications, capacity, facility locations, and regulatory track records. You can use this data as a qualified shortlist before requesting quotes directly.

Q.Can I filter by specific regulatory approvals like FDA or EMA?

Yes. You can specify the regulatory authority or geography relevant to your filing strategy, and the dataset will prioritize CDMOs with demonstrated inspection history from those agencies.

Q.How current is the capacity and facility data?

Data is gathered from public sources at the time of your request—not from a static database. This means expansion announcements, new GMP certifications, and facility updates are captured as soon as they appear on the public web.